We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lumoxiti

News List

AstraZeneca’s Lumoxiti secures FDA nod to treat hairy cell leukaemia pharmaceutical-technology
September 21, 2018
AstraZeneca and its research and development arm MedImmune have obtained approval from the US Food and Drug Administration (FDA) for the use of Lumoxiti to treat adults with relapsed or refractory hairy cell leukaemia.
FDA Approves New Kind of Treatment for Hairy Cell Leukemia americanpharmaceuticalreview
September 18, 2018
The U.S. Food and Drug Administration (FDA) approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients...
FDA Approves Lumoxiti drugs
September 14, 2018
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemi